Items where Funder is Alzheimer’s Research UK.

ARUK-SRF2017B-1

Mak, E. orcid.org/0000-0002-6437-8024, Dounavi, M.-E. orcid.org/0000-0001-8287-346X, Operto, G. et al. (84 more authors) (2024) APOE ɛ4 exacerbates age-dependent deficits in cortical microstructure. Brain Communications, 6 (1). fcad351. ISSN 2632-1297

Low, A., Prats-Sedano, M.A., Stefaniak, J.D. et al. (11 more authors) (2022) CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults : the PREVENT-Dementia study. Journal of Neurology, Neurosurgery & Psychiatry, 93 (5). pp. 481-490. ISSN 0022-3050

Kucikova, L. orcid.org/0000-0002-0769-9542, Danso, S., Jia, L. et al. (1 more author) (2022) Computational psychiatry and computational neurology : seeking for mechanistic modeling in cognitive impairment and dementia. Frontiers in Computational Neuroscience, 16. 865805. ISSN 1662-5188

Kucikova, L. orcid.org/0000-0002-0769-9542, Zeng, J., Muñoz-Neira, C. et al. (6 more authors) (2023) Genetic risk factors of Alzheimer’s Disease disrupt resting-state functional connectivity in cognitively intact young individuals. Journal of Neurology, 270. pp. 4949-4958. ISSN 0340-5354

Huang, W., Zeng, J., Jia, L. et al. (5 more authors) (2023) Genetic risks of Alzheimer’s by APOE and MAPT on cortical morphology in young healthy adults. Brain Communications, 5 (5). ARTN fcad234. ISSN 2632-1297

McKiernan, E. orcid.org/0000-0001-7076-8216, Su, L. orcid.org/0000-0002-6347-3986 and O’Brien, J. (2023) MRS in neurodegenerative dementias, prodromal syndromes and at-risk states: A systematic review of the literature. NMR in Biomedicine. e4896. ISSN 0952-3480

Low, A., Prats-Sedano, M.A., McKiernan, E. et al. (15 more authors) (2022) Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia study. Alzheimer’s Research & Therapy, 14 (1). 154. ISSN 1758-9193

Payne, T., Appleby, M., Buckley, E. et al. (16 more authors) (2023) A double‐blind, randomized, placebo‐controlled trial of ursodeoxycholic acid (UDCA) in Parkinson's disease. Movement Disorders. ISSN 0885-3185